BR112021026789A2 - Sialidases humanas recombinantes, proteínas de fusão de sialidase e métodos de uso das mesmas - Google Patents

Sialidases humanas recombinantes, proteínas de fusão de sialidase e métodos de uso das mesmas

Info

Publication number
BR112021026789A2
BR112021026789A2 BR112021026789A BR112021026789A BR112021026789A2 BR 112021026789 A2 BR112021026789 A2 BR 112021026789A2 BR 112021026789 A BR112021026789 A BR 112021026789A BR 112021026789 A BR112021026789 A BR 112021026789A BR 112021026789 A2 BR112021026789 A2 BR 112021026789A2
Authority
BR
Brazil
Prior art keywords
sialidase
fusion proteins
methods
recombinant human
sialidase fusion
Prior art date
Application number
BR112021026789A
Other languages
English (en)
Portuguese (pt)
Inventor
S Turner Andrew
Li Peng
Lihui Xu
Lizhi Cao
A Shelke Sandip
Original Assignee
Palleon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palleon Pharmaceuticals Inc filed Critical Palleon Pharmaceuticals Inc
Publication of BR112021026789A2 publication Critical patent/BR112021026789A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
BR112021026789A 2019-07-03 2020-07-03 Sialidases humanas recombinantes, proteínas de fusão de sialidase e métodos de uso das mesmas BR112021026789A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962870403P 2019-07-03 2019-07-03
US202062957011P 2020-01-03 2020-01-03
PCT/US2020/040828 WO2021003469A2 (en) 2019-07-03 2020-07-03 Recombinant human sialidases, sialidase fusion proteins, and methods of using the same

Publications (1)

Publication Number Publication Date
BR112021026789A2 true BR112021026789A2 (pt) 2022-05-10

Family

ID=74101301

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021026789A BR112021026789A2 (pt) 2019-07-03 2020-07-03 Sialidases humanas recombinantes, proteínas de fusão de sialidase e métodos de uso das mesmas

Country Status (9)

Country Link
US (1) US20220356457A1 (https=)
EP (1) EP3994275A4 (https=)
JP (2) JP7777988B2 (https=)
KR (1) KR20220032576A (https=)
CN (1) CN114258431A (https=)
AU (1) AU2020301037A1 (https=)
BR (1) BR112021026789A2 (https=)
CA (1) CA3145676A1 (https=)
WO (1) WO2021003469A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102914621B1 (ko) 2018-01-03 2026-01-21 팔레온 파마슈티칼스 인크. 재조합 인간 시알리다제, 시알리다제 융합 단백질, 및 이를 사용하는 방법
BR112021026852A2 (pt) * 2019-07-03 2022-02-22 Palleon Pharmaceuticals Inc Sialidases recombinantes e métodos de uso das mesmas
US20220387616A1 (en) * 2019-07-03 2022-12-08 Palleon Pharmaceuticals Inc. Sialidase-her2-antibody fusion proteins and methods of use thereof
JP7777988B2 (ja) * 2019-07-03 2025-12-01 パレオン ファーマシューティカルズ インコーポレイテッド 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびその使用方法
WO2025217138A1 (en) * 2024-04-09 2025-10-16 Palleon Pharmaceuticals Inc. Recombinant human sialidases, sialidase fusion proteins, and methods of using the same
WO2026037175A1 (zh) 2024-08-16 2026-02-19 上海宝济药业股份有限公司 靶向靶细胞的复合物及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE474925T1 (de) * 1993-05-17 2010-08-15 Genentech Inc Rekombinante cho zell sialidase
US8512710B2 (en) * 2002-11-22 2013-08-20 Ansun Biopharma, Inc. Class of therapeutic protein based molecules
WO2007108464A1 (ja) * 2006-03-20 2007-09-27 Kyowa Hakko Kogyo Co., Ltd. 哺乳動物由来細胞質シアリダーゼに対する抗体
CN100376689C (zh) * 2006-03-28 2008-03-26 北京大学 一种预测达菲类药物用药安全性的方法
CN101896616B (zh) * 2007-10-12 2014-06-04 西格马-奥利奇股份有限公司 提高糖蛋白唾液酸化作用的组合物与方法
AU2010270979B2 (en) * 2009-06-22 2015-04-23 Medimmune, Llc Engineered Fc regions for site-specific conjugation
JP2013510169A (ja) * 2009-11-06 2013-03-21 ネクスバイオ，インク． 呼吸器管の治療及び予防のための方法、化合物、及び組成物
US10081801B2 (en) * 2013-04-12 2018-09-25 Danmarks Tekniske Universitet Mutant sialidase having trans-sialidase activity for use in production of sialylated glycans
WO2018006066A1 (en) * 2016-07-01 2018-01-04 The Board Of Trustees Of The Leland Stanford Junior University Inhibitory immune receptor inhibition methods and compositions
MX2018016393A (es) * 2016-07-01 2019-08-12 Univ Leland Stanford Junior Conjugados para la edición de la superficie de la celula diana.
DK3630968T3 (da) * 2017-05-26 2024-07-29 Genovis Ab Enzymer til glycananalyse
KR102914621B1 (ko) * 2018-01-03 2026-01-21 팔레온 파마슈티칼스 인크. 재조합 인간 시알리다제, 시알리다제 융합 단백질, 및 이를 사용하는 방법
WO2020142727A1 (en) * 2019-01-03 2020-07-09 Palleon Pharmaceuticals Inc. Methods and compositions for treating cancer with immune cells
JP7777988B2 (ja) * 2019-07-03 2025-12-01 パレオン ファーマシューティカルズ インコーポレイテッド 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびその使用方法

Also Published As

Publication number Publication date
JP2026032063A (ja) 2026-02-25
WO2021003469A2 (en) 2021-01-07
EP3994275A2 (en) 2022-05-11
CA3145676A1 (en) 2021-01-07
WO2021003469A3 (en) 2021-04-08
JP2022538894A (ja) 2022-09-06
KR20220032576A (ko) 2022-03-15
EP3994275A4 (en) 2023-11-29
US20220356457A1 (en) 2022-11-10
CN114258431A (zh) 2022-03-29
JP7777988B2 (ja) 2025-12-01
AU2020301037A1 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
BR112021026789A2 (pt) Sialidases humanas recombinantes, proteínas de fusão de sialidase e métodos de uso das mesmas
MX2020007024A (es) Sialidasas humanas recombinantes, proteinas de fusion de sialidasa y metodos para usar las mismas.
CL2020003096A1 (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
BR112021021843A2 (pt) Composições de proteína de fusão quimicamente projetada e métodos de uso das mesmas
MX2022005252A (es) Composiciones de escherichia coli y metodos de las mismas.
BR112018068189A2 (pt) proteínas de ligação induzíveis e métodos de uso
PH12021500031A1 (en) Anti-il2 receptor gamma antigen-binding proteins
BR112015021979A2 (pt) Anticorpos humanos para grem1
BR112018070676A2 (pt) construtos de ligação a antígeno multiespecífico que têm como alvo agentes imunoterapêuticos
BR112019000098A2 (pt) proteína de fornecimento ao cérebro, método de tratamento e/ou profilaxia de distúrbios cerebrais em mamíferos que possuem ou encontram-se em risco de desenvolver o mencionado distúrbio e método de diagnóstico e/ou detecção de distúrbios cerebrais em mamíferos suspeitos de possuir ou que se encontram em risco de desenvolver o mencionado distúrbio
BRPI0819909B8 (pt) anticorpo sintético humano ou humanizado isolado ou um fragmento funcional do mesmo, fragmento funcional e composição farmacêutica
BR112016013347A2 (pt) anticorpo monoclonal humano neutralizante anti-il-33
BR112015017307A2 (pt) composições de espécies com baixa acidez e métodos para produção e uso das mesmas
BR112016014810A2 (pt) Antagonistas de fcrn e métodos de uso
BR112018010160A2 (pt) inibidor da c1 esterase humana recombinante e usos do mesmo
BR112022011570A2 (pt) Anticorpos anti-mertk e métodos de uso dos mesmos
BR112017021484A2 (pt) anticorpos de direcionamento à proteína morfogenética óssea 9 (bmp9) e métodos para os mesmos
BR112021025077A2 (pt) Anticorpos anti-sortilina para uso em terapia
BR112014024751A2 (pt) antígenos de clostridium difficile
BR112017017609A2 (pt) proteína de fusão fc, e, composição farmacêutica.
BR112021016791A2 (pt) Proteínas de ligação de antígenos que se ligam a bcma
BR112022008653A2 (pt) Conjugado anticorpo-fármaco, método para tratar câncer, e, uso do conjugado anticorpo-fármaco
MX2023000243A (es) Sialidasas recombinantes con sensibilidad reducida a la proteasa, proteinas de fusion de sialidasa y metodos para utilizarlas.
PH12018502275B1 (en) Interferon beta antibodies and uses thereof
BR112022007776A2 (pt) Composições e métodos para minimizar a perda de proteína em baixas concentrações de proteína